Core Insights - The company reported a revenue of 5.927 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 13.02% [1] - The net profit attributable to shareholders was 93.11 million yuan, down 57.93% year-on-year [1] - The net profit after deducting non-recurring items was 89.69 million yuan, reflecting a decrease of 58.35% year-on-year [1] - The basic earnings per share stood at 0.0117 yuan [1]

Core Viewpoint - Hebang Biotechnology (603077.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 5.927 billion yuan, representing a year-on-year decrease of 13.02% [1] - The net profit attributable to shareholders was 93.1085 million yuan, down 57.93% year-on-year [1] - The basic earnings per share were 0.0117 yuan [1]

证券代码：603077 证券简称：和邦生物 公告编号：2025-048 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 注 3：营养剂及中间体、副产品包括：蛋氨酸、甲硫醇钠、硫酸铵等； 注 4：上述统计数据中：产量不包含内部领用部分，销量不包含内部销售部分。 二、主要产品和原材料价格（不含税）变动情况 （一）主要产品价格（不含税）变动情况 2025年1-9月公司主要化工产品价格变动情况如下： 2025 年 1-9 月主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三 号——化工》及相关要求，四川和邦生物科技股份有限公司（以下简称"公司"） 现将 2025 年 1-9 月主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 联碱化工类产品 | 1,339,705.53 | 931,3 ...

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 三、本次调整印尼项目产能对公司的影响 四川和邦生物科技股份有限公司 对外投资进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 四川和邦生物科技股份有限公司（以下简称"公司"）分别于 2023 年 8 月 30 日、2024 年 8 月 9 日在上海证券交易所网站（http://www.sse.com.cn）及指 定信披媒体披露了《和邦生物关于签署<合作投资意向书>等的公告》及《和邦生 物对外投资进展公告》，就公司投资印尼项目的具体情况和进展进行了披露。 二、对外投资进展情况 经公司通过与潜在客户不断的沟通交流，为充分响应客户对我司草甘膦产品 的需求，决定将广安年产 50 万吨双甘膦产品全部制成草甘膦。为匹配前述调整， 公司计划将印尼项目中的草甘膦生产规模从20万吨/年调整到35万吨/年。同时， 印尼项目中计划实施的 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-047 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 第六届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）第六届董事会第二十 六次会议通知于2025年10月24日分别以专人送达、电子邮件或传真等方式发出， 会议于2025年10月28日以现场结合通讯表决方式召开。 本次会议由公司董事长曾小平先生召集并主持。应到董事 9 名,实到董事 9 名。会议的召集、召开符合有关法律、行政法规、部门规章和《四川和邦生物科 技股份有限公司章程》的规定，表决所形成的决议合法、有效。会议审议通过了 如下议案： 一、审议通过《四川和邦生物科技股份有限公司 2025 年第三季度报告》 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）及公司 指定信息披露媒体（以下简称"上交所网站"）披露的公司 2025 年第三季度报告。 表决结果：同意 9 票，反对 0 票， ...

Financial Performance - The company's revenue for the third quarter reached ¥2,005,467,579.31, an increase of 2.05% compared to the same period last year[4] - The total profit for the quarter was ¥115,440,397.13, showing a significant increase of 714.07% year-on-year[4] - Net profit attributable to shareholders was ¥41,337,014.44, reflecting a year-on-year increase of 42.30%[4] - Basic earnings per share for the quarter were ¥0.0052, up 44.44% compared to the previous year[5] - Diluted earnings per share for the quarter were ¥0.0040, a decrease of 66.04% year-to-date[5] - Total operating revenue for the first three quarters of 2025 was CNY 5,926,520,025.82, a decrease of 13.0% compared to CNY 6,813,692,192.92 in the same period of 2024[22] - The net profit for the first three quarters of 2025 is CNY 76,442,914.44, a decrease of 60.96% compared to CNY 195,536,979.04 in the same period of 2024[23] - The total operating profit for the first three quarters of 2025 is CNY 184,809,095.44, down from CNY 260,299,739.07 in 2024, indicating a decline of 29.00%[23] - The company reported a total comprehensive income of CNY 58,180,082.18 for the first three quarters of 2025, significantly lower than CNY 162,460,496.75 in 2024, reflecting a decrease of 64.16%[24] - Basic earnings per share for the first three quarters of 2025 is CNY 0.0117, down from CNY 0.0268 in the same period of 2024[24] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥310,136,527.38[4] - The company's cash and cash equivalents as of September 30, 2025, were CNY 6,821,397,689.82, compared to CNY 6,999,422,872.19 at the end of 2024[17] - The cash and cash equivalents at the end of the third quarter of 2025 amount to CNY 6,804,095,547.13, compared to CNY 2,366,528,042.25 at the end of the same period in 2024[27] - The company incurred a net cash outflow from investing activities of CNY -783,711,438.39 in the first three quarters of 2025, slightly higher than CNY -764,509,543.20 in 2024[27] - The net cash inflow from financing activities for the first three quarters of 2025 is CNY 447,894,221.34, an increase from CNY 367,705,639.89 in 2024[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥29,293,992,581.26, a decrease of 1.20% from the end of the previous year[5] - Total assets as of September 30, 2025, were CNY 29,293,992,581.26, slightly down from CNY 29,649,734,539.88 at the end of 2024[19] - Total liabilities decreased to CNY 10,528,477,892.01 in 2025 from CNY 10,643,216,334.24 in 2024, a reduction of 1.1%[19] - The company's equity attributable to shareholders was CNY 18,522,695,742.31 as of September 30, 2025, compared to CNY 18,626,392,431.87 at the end of 2024[19] Sales and Product Performance - The company reported a significant increase in the sales of glyphosate and methionine products, contributing to the profit growth[8] - The company experienced a decline in sales and prices of soda ash and glass products, impacting year-to-date net profit negatively by 57.93%[9] Investments and Projects - The company holds a total of 41 mineral resources, with 2 salt mining rights in normal production and 9 domestic mining rights under various stages of development[14] - The company has completed part of the large equipment procurement for its Guang'an 500,000 tons/year glyphosate project, with 490 contracts signed totaling 179,771,000 RMB[16] - The company has made progress on its Indonesia 350,000 tons/year glyphosate project, with 61 contracts signed totaling 21,155,000 RMB[16] - The company has a design annual production capacity of 1 million tons for the Yanfeng Phosphate Mine, with a total reserve of 3,174.10 tons[14] - The Liujiashan Phosphate Mine has a total reserve of 5,917.80 tons and is currently under construction[14] - The company has initiated preliminary exploration work for the Wonarah Phosphate Mine in Australia, with core area reserves estimated at 6,600 tons[15] - The company has completed initial exploration plans for lithium mines in Nigeria, with a 50% interest in the projects[15] - The company is currently at 40% progress in initial exploration work for the Kudi Copper Mine in Xinjiang[14] Research and Development - Research and development expenses decreased to CNY 12,370,674.89 in 2025 from CNY 22,518,887.99 in 2024, reflecting a reduction of 45.0%[22] Credit and Receivables - Accounts receivable increased to CNY 1,058,656,332.41 in 2025 from CNY 809,763,164.93 in 2024, representing a growth of 30.7%[17] - The net credit impairment loss increased to CNY -22,193,435.84 in 2025 from CNY -9,321,151.14 in 2024, indicating a worsening in credit quality[22] Other Comprehensive Income - The company reported a decrease in other comprehensive income after tax, amounting to CNY -18,262,832.26 for the first three quarters of 2025, compared to CNY -33,076,482.29 in 2024[23]

Market Overview - The agricultural chemical sector saw a slight increase of 0.02% on October 28, with Chengxing Co. leading the gains [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Top Performers - Chengxing Co. (600078) closed at 9.63, up 10.06% with a trading volume of 515,900 shares and a transaction value of 479 million [1] - Dongfang Tieta (002545) closed at 16.87, up 7.25% with a trading volume of 599,200 shares and a transaction value of 1.012 billion [1] - Suli Co. (603585) closed at 20.14, up 5.33% with a trading volume of 103,800 shares and a transaction value of 204 million [1] Underperformers - Nongxin Technology (001231) closed at 25.66, down 10.00% with a trading volume of 170,100 shares and a transaction value of 466 million [2] - Lanfeng Biochemical (002513) closed at 8.00, down 8.05% with a trading volume of 744,400 shares and a transaction value of 607 million [2] - Lianhua Technology (002250) closed at 11.40, down 5.94% with a trading volume of 858,700 shares and a transaction value of 983 million [2] Capital Flow - The agricultural chemical sector experienced a net outflow of 222 million from institutional investors, while retail investors saw a net inflow of 181 million [2] - The top net inflows from retail investors were observed in Dongfang Tieta (002545) with 78.43 million, while Chengxing Co. (600078) saw a net outflow of 42.07 million [3]

Group 1 - The core point of the article is the establishment of a new mining company by Hebang Biological, with a registered capital of 100 million yuan [1] - The newly formed company, Mianing Hebang Mining Co., Ltd., will engage in non-coal mining resource extraction and mineral resource exploration [1] - Hebang Biological holds 100% ownership of the new mining company [1]

Core Viewpoint - Recently, a new company named Mianing Hebang Mining Co., Ltd. was established with a registered capital of 100 million yuan, focusing on non-coal mining resource extraction and geological exploration of both metal and non-metal resources [1] Company Summary - Mianing Hebang Mining Co., Ltd. has a registered capital of 100 million yuan [1] - The company is fully owned by Hebang Biological (603077) [1] - The business scope includes non-coal mining resource extraction, mineral resource exploration, and geological exploration of metal and non-metal resources [1]

Core Viewpoint - The report highlights the growth of China's soda ash (sodium carbonate) production, indicating a positive trend in the industry with a year-on-year increase in production figures for 2025 [1] Industry Summary - As of August 2025, China's soda ash production reached 3.28 million tons, reflecting a year-on-year growth of 3.8% [1] - Cumulative production from January to August 2025 totaled 26.254 million tons, with a cumulative growth rate of 3.4% [1] - The data is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - Listed companies in the soda ash sector include: Yuanxing Energy (000683), Sanyou Chemical (600409), Shandong Haihua (000822), Shuanghuan Technology (000707), Chlor-Alkali Chemical (600618), Jinjing Technology (600586), Hubei Yihua (000422), Yuntu Holdings (002539), and Hebang Biotechnology (603077) [1] - The report provides insights into the competitive strategies and market analysis for the soda ash industry from 2025 to 2031 [1]